Proteins such as tau, Aβ, and α-synuclein within EVs can be utilized for the staging and early diagnosis of neurodegenerative diseases, and drug delivery through EVs is also being developed as a therapeutic strategy targeting the brain. This evidence concerns the gene MAPT and neurodegenerative disease.